消化性溃疡治疗的药物经济学分析

Pharmacoeconomic Analysis on Treatment of Peptic Ulcer

目的评价3种三联疗法治疗幽门螺旋杆菌(HP)感染消化性溃疡的成本-效果,促进临床合理用药。方法选取HP阳性的消化性溃疡患者135例,分成3组。其中奥美拉唑组(OAC组)41例,泮托拉唑组(PAC组)44例,雷贝拉唑组(RAC组)50例。3组均加服克拉霉素与阿莫西林,比较用药14d后的疗效、不良反应和治疗成本,并进行药物经济学成本-效果分析。结果 3组治疗方案的成本分别为717.36元、777.84元、1060.92元;HP根除率分别为87.80%,90.91%,94.00%,3组无显著性差异;溃疡愈合率分别为78.05%,93.18%,96.00%,OAC组与PAC组比较有显著性差异。结论 PAC组是治疗消化性溃疡的最佳治疗方案。

Objective To assess the cost- effectiveness of 3 kinds of triple therapy schemes in treating peptic ulcer with Helicobacter pylori （HP） infection for promoting clinical rational medication. Methods 135 patients with HP positive peptic ulcer were divided into three groups： the omeprazole group （OAC, n=41）, the pantoprazole group（PAC, n=44） and rabeprazole （RAC, n=50）.The three groups were added with oral clarithromycin and amoxicillin. The curative effects,adverse reactions and treatment costs after 14 d treatment were compared among 3 groups by cost-effectiveness method. Results The costs of the OAC,PAC and RAC groups were 717.36 Yuan, 777.84 Yuan and 1 060.92 Yuan respectively;the HP eradication rates were 87.80% ,90. 91% and 94. 00% ,without statistical differ- ence;the ulcer healing rates were 78.05% ,93.18% and 96.00% respectively,there was statistical difference between the OAC group and PAC group. Conclusion The PAC group is the optimal therapy scheme for treating HP positive peptic lcer